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Crimean-Congo hemorrhagic fever (CCHF) has been
reported from more than 30 countries around the world.
Ribavirin is the only drug which has in vitro effect on
CCHF virus. Although there is a debate on the clinical
benefit of ribavirin, some experts from the endemic areas
strongly recommend ribavirin in patients with CCHF based
on in vitro activity and rare adverse events with short-
term use1. Here, we report bradycardia in a patient with
CCHF related to high dose ribavirin administration.
Case history
A 57-yr old man was admitted to hospital with fever,
fatigue and epistaxis. He was living in an endemic area of
CCHF and had history of tick bite four days previously.
The physical examination was unremarkable except fever
of 38.2°C. Laboratory tests were as follows: White blood
cells (WBC) 1.9 x 109/l (neutrophils 90%); hemoglobin
was 11.3 g/l; thrombocyte count  was 128 x 109/l. The
level of aspartate aminotransferase (AST) was 97 U/l;
alanine aminotransferase (ALT) was 55 U/l; lactate dehy-
drogenase (LDH) was 510 U/l; Gama-glutamyl  trans-
ferase (GGT) was 20 U/l; total bilirubin was 0.7 mg/dl;
prothrombin time was 13 sec; activated partial thrombo-
plastin time was 35 sec; and International Normalized
Ratio (INR) was 1.18. The renal function tests and serum
electrolytes were in normal range. On third day of follow-
up thrombocytes decreased to 43 x 109/l and then 18 x
109/l. AST and ALT increased to 431 and 189 U/l. Fever
continued to spike and ribavirin ( 2 g loading then 4 g/day
maintenance) was started with thrombocyte replacement.
After three days of  ribavirin treatment bradycardia (heart
rate of 30–40/min) developed. Electrocardiograpy was
normal except sinusoidal bradycardia. Echocardiography
and ambulatuar holter record for 24 h did not reveal any
pathologic finding. Serum electrolytes were in normal
range. Ribavirin was stopped on fourth day and the heart
rate became normal one day later. Clinical diagnosis of
CCHF was confirmed by ELISA test that was performed
at Refik Saydam National Public Health Agency (RSHM),
the reference laboratory for CCHF. On the sixth day of
admission fever was resolved and laboratory findings im-
proved as WBC 3.7 x 109/l; hemoglobin 13.3 g/l; thromb-
ocytes  166 x 109/l; AST: 127 U/l; ALT: 131 U/l; ALP: 89
U/l; GGT: 78 U/l; and LDH: 387 U/l. He was discharged in
good condition on the 10th day of hospitalization.
DISCUSSION
Cardiac involvement was reported in patients with
CCHF based on echocardiography findings2. Two recent
studies evaluated the electrocardiography of 49 adult and
23 pediatric patients with CCHF.  Although T-wave nega-
tivity or bundle branch block was detected in adult pa-
tients,  rhythm  abnormality was not detected in any pa-
tient3, 4.  In our patient, cardiac involvement was ruled out
with completely normal echocardiography. The main ad-
verse events related to high dose ribavirin were reversible
hemolytic anemia and hypomagnesemia in patients with
hemorrhagic fever with renal syndrome (HFRS). Brady-
cardia was reported in three of 34 patients who received
high dose ribavirin. However, bradycardia was also de-
tected as the manifestation of the disease  in 19–73% of
individuals with HFRS, and in this setting it is very diffi-
cult to make a differential diagnosis either bradycardia
developed  because of the cardiac involvement of HFRS
or related to ribavirin treatment5. Rhythm abnormality was
not detected as an adverse effect in the studies which evalu-
ated the role of oral or intravenous ribavirin in the treat-
ment of CCHF1, 6, 7. To the best of our knowladge, this is
the first case reporting bradycardia related to ribavirin
treatment in a patient with CCHF.  It can be concluded
that physicians who use ribavirin in the treatment of CCHF
should be careful about the rare adverse events related to
this drug. J Vector Borne Dis 49, September 2012 194
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